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Abstract: Seizures are the result of a sudden and temporary synchronization of neuronal activity, the reason for which is 
not clearly understood. Astrocytes participate in the control of neurotransmitter storage and neurotransmission efficacy. 
They provide fuel to neurons, which need a high level of energy to sustain normal and pathological neuronal activities, 
such as during epilepsy. Various genetic or induced animal models have been developed and used to study epileptogenic 
mechanisms. Methionine sulfoximine induces both seizures and the accumulation of brain glycogen, which might be con-
sidered as a putative energy store to neurons in various animals. Animals subjected to methionine sulfoximine develop 
seizures similar to the most striking form of human epilepsy, with a long pre-convulsive period of several hours, a long 
convulsive period during up to 48 hours and a post convulsive period during which they recover normal behavior. The ac-
cumulation of brain glycogen has been demonstrated in both the cortex and cerebellum as early as the pre-convulsive pe-
riod, indicating that this accumulation is not a consequence of seizures. The accumulation results from an activation of 
gluconeogenesis specifically localized to astrocytes, both in vivo and in vitro. Both seizures and brain glycogen accumula-
tion vary when using different inbred strains of mice. C57BL/6J is the most “resistant” strain to methionine sulfoximine, 
while CBA/J is the most “sensitive” one. The present review describes the data obtained on methionine sulfoximine de-
pendent seizures and brain glycogen in the light of neurotransmission, highlighting the relevance of brain glycogen con-
tent in epilepsies.  
Keywords: Epilepsy, methionine sulfoximine, chemically-induced epilepsy, glycogen, astrocytes, glycogenesis, gluconeogene-
sis. 
1. INTRODUCTION 
Glutamate and -aminobutyric acid (GABA) are the most 
abundant neurotransmitters in the central nervous system 
(CNS). The action potential transmission operated by the 
excitatory amino-acid glutamate is mediated through two 
kinds of receptors: (i) ionotropic receptors and (ii) me-
tabotropic receptors. Three classes of ionotropic receptors to 
glutamate are commonly described, i.e. AMPA (-amino-3-
hydroxy-5-methylisoazol-4-propionate), NMDA (N-methyl-
D-aspartate) and kainate (kainic acid) receptors. The activa-
tion of these receptors induces a K
+ ion outward and a Na
+ 
ion inward transport, which in turn induces activation of 
action potential. Two types of the GABA receptors have 
been described: GABAA and GABAB. The activation of 
GABAA receptors induces an inward entry of chloride ions, 
while that of GABAB receptors induces an outflow of K
+ 
ions, both actions lead to an inhibition of neuronal activity. 
These two complementary and contradictory neurotransmis-
sion pathways constitute the targets for most antiepileptic 
drugs. Besides neurons, glial cells constitute the majority of 
brain cells and are of four types: (i) ependymocytes, (ii) 
microgliocytes, (iii) oligodendrocytes and (iv) astrocytes. 
Astrocytes are the more abundant glial cells, and they have 
numerous functions including their contribution to neuro-
genesis [1-3] and synaptogenesis [3-8]. Moreover, the end-
feet of astrocytes are also involved in various functions. 
Epilepsy is characterized by many symptoms which are 
manifestations of the various clinical forms of the condition. 
The World Health Organization (WHO) recognizes at least 
40 forms [9-14], which correspond to a sudden and tempo-
rary synchronization of neuron activities whose origins are  
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not well understood [15-20]. The balance between excitatory 
and inhibitory neurons, basically the equilibrium between 
glutamatergic and GABAergic neurons, controls temporary 
neuron synchronization. The knowledge of this disequilib-
rium is one of the keys to a cure for epilepsies. Searches for 
epileptic mechanisms are based upon clinical approaches, 
and the need to know where the epileptic foci are localized. 
Such localization depends on both EEG and medical image-
ries. The latter are based upon various mechanisms, and the 
uptake of glucose analogs represents one of them [21-23]. As 
humans cannot constitute an adequate experimental model 
for studying the mechanisms responsible for seizures various 
animal models have been developed and used for this pur-
pose. 
The present review briefly describes human epilepsies 
and animal models developed to study this disease, as well as 
data obtained for methionine sulfoximine (MSO) dependent 
seizures and brain glycogen accumulation. The review high-
lights the relevance of brain glycogen content in epilepsies. 
Brain glycogen will be determined in vivo in the near future, 
either in animals or in humans, and might therefore be used 
as a diagnostic tool as well as a therapeutic target. 
2. EPILEPSY IN HUMAN AND ANIMALS 
Epilepsy is a neurological disorder characterized by sud-
den and temporary bursts of a group of neurons for focal 
epilepsy, or of “whole” cortex when the crisis is generalized. 
When febrile epilepsies are excluded, epilepsy affects up to 
1% of the population [24]. The most striking form of human 
epilepsy, the former so-called “grand-mal”, has enormous 
consequences. It can lead to a difficult life in affected pa-
tients, some of who may die from status epilepticus. The 
reasons why a group of neurons suddenly and temporarily 
synchronize their activity are not well understood, and need 
clarification. A better understanding of the condition will 
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edge, which will enable the development of new therapeutic 
approaches with benefits to patients. Such advances are 
being based on studies of specific forms of human epilepsies; 
and although research on human epilepsies is limited, for 
deontological reasons, it is needed in order to fit the physio-
logical conditions of this disease. Animal models of experi-
mental epilepsies have therefore been developed and widely 
used, and are essentially classified into three groups: (i) 
genetic models, (ii) models in which crisis is induced by 
external stimuli, such as chemical or physical agents and (iii) 
models in which the responses to external stimuli depend on 
the genetic background. 
Animal models mimicking human epilepsies are peculiar, 
and each animal model most likely concerns a specific as-
pect, or a mixture of some aspects of the variety of human 
epilepsies. Nonetheless these models have high utility and 
are an important prerequisite for research into epilepsy, as 
they allow us to approach specific point(s) of the human 
pathology experimentally. They are also powerful, making it 
possible to pinpoint a specific aspect of epilepsy and to ana-
lyze it in a “simpler” context than in human pathology.  
3. EPILEPTOGENESIS 
The understanding of the process by which a normal 
brain becomes epileptic, epileptogenesis, may help to iden-
tify molecular targets for drugs that could prevent epilepsy, 
as the current pharmacological therapy is only symptomatic 
and never cures the illness. The basic structure and function-
ing of the neuronal network is well understood, and below 
we take the example of the network of the cerebral cortex. 
3.1. EEG Formation 
The pyramidal cells are the major projection neurons of 
the cerebral cortex, and they project their axons into other 
areas of the brain and the spinal cord. They are excitatory 
neurons and principally use glutamate as a neurotransmitter. 
These cells exhibit a large number of collaterals that spread 
inside the cerebral cortex, and their dendrites often cross 
several layers of the cerebral cortex and are oriented perpen-
dicular to the surface of the brain. A second kind of cell in 
the cerebral cortex is the interneural stellate cells that spread 
their axons vertically in the plane of the cortical column. 
Stellate cells get action potentials from the thalamus, and 
convey them to other interneurons or to pyramidal cells in 
the same column. A third kind of cerebral cortex cells are the 
basket cells, that are interneurons, which horizontally ori-
ented their axons toward neuron somas. The latter axons 
envelop the somas and are able to inhibit them using the 
neurotransmitter GABA. These preceding three kinds of 
neurons are the main substratum of EEG genesis through the 
so-called theory of volume conduction [25-28]. The recorded 
potential from a large number of neurons is of course the 
sum of the electric activity of individual neurons. The excita-
tory post-synaptic potential of an individual neuron is the 
result of an inward current, and it spreads as an extracellular 
voltage outside the neuron membrane. Its magnitude (micro-
volt range) is too small to be recorded on the scalp, but when 
many neurons are taken into account, with large EEG elec-
trodes, such a recording becomes possible. Because of the 
orientation described above, it is believed that EEG princi-
pally comes from pyramidal neurons, since the contribution 
of the other kinds of cell is almost negligible. It is not easy to 
distinguish an EEG coming solely from the pyramidal cells, 
or from a modulation of these pyramidal activities by other 
neurons, as pyramidal neurons are connected to the thalamus 
that synchronously activates a large number of these neu-
rons. The main component of EEG is surely extracellular 
potentials deriving from excitatory post-synaptic potentials, 
since the latter are slow and can summate [29, 30]. The con-
tribution of action potentials may exist but may be negligi-
ble, because its rapidity makes it difficult to summate.  
3.2. Genesis of Epileptic Waves 
It is possible to observe a large amplitude in the EEG in 
alpha, theta, and delta waves, which is due to a synchroniza-
tion of the activities of groups of neurons [31-33], after 
which a normal EEG is observed. In the case of epilepsy a 
temporary synchronization occurs, although its level is high 
and it generates large spikes and spikes and waves. Moreo-
ver, the synchronization is recurrent. The actual cause of 
such a synchronization is not well understood [15-20]. In 
experiments using a topic application of penicillin it was 
shown that GABA inhibition is blocked. Action potentials 
are concomitant with the EEG spikes when the individual 
neuron activities are recorded at the same time. Each neuron 
makes its own action potential when its threshold of depo-
larization is reached in a normal brain, but the fundamental 
question of epileptogenesis is why neighboring neurons all 
make their action potential at the same time? The current 
believe of a decrease in inhibition of pyramidal neurons is 
not convincing. Indeed, if such a decreased inhibition is 
favorable for an increased firing of a given individual neu-
ron, it does not explain why a group of thousands of neurons 
make their action potentials simultaneously. Some specula-
tions have been proposed [15-20]. A pyramidal cell does not 
excite its neighboring pyramidal cell in a normal situation, 
but in epileptic foci such an excitation may occur [34], al-
though the mechanism of this excitation remains unclear. 
One possibility is an increase in the extracellular potentials 
described above. In the epileptic situation, extracellular 
potential at the level of the soma of a given pyramidal cell 
could be too high, and it could excite the neighbor pyrami-
dal cells, but this possibility is not tenable without a solid 
experimental demonstration. The soma of the pyramidal 
cells is “enveloped” in glial cells, principally in non-
myelinating oligodendrocytes and astrocytes, so that the 
spread of extracellular potentials up to the adjacent py-
ramidal cells is improbable, unless abnormalities exist in 
the enveloping glial cells. This observation poses the ques-
tion of a possible involvement of glial cells in epilepto-
genesis [35-43]. 
4. NEURAL CELLS, NEUROTRANSMISSION, EN-
ERGY METABOLISM 
Glial cells are no longer regarded as the “glue” between 
neurons, but have many roles necessary to sustain brain 
functions. In 2003 Ben Barres [44] claimed: “…virtually 
every aspect of brain development and function involves a 
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sider glia as passive support cells.” Indeed, oligodendrocytes 
and Schwann cells are necessary for high-speed neurotrans-
mission by ensheathing axons and generating nodes of Ran-
vier. These cells provide insulation and trophic factors to 
neurons. Moreover, the most abundant glial cells, the astro-
cytes, have come to be considered as an important partner in 
neurotransmission, and also in terms of regulators of energy 
provided to neurons. Many roles in fact are now attributed to 
astrocytes [44, 45]. 
4.1. Astrocytes as Partners in Neurotransmission 
The relevance of glial cells in controlling neurogenesis 
and synaptogenesis has only recently been acknowledged, 
presumably because the alteration in the preceding processes 
during development could explain childhood epilepsies. 
Furthermore, the end-feet of astrocytes surround the capillar-
ies, and therefore contribute to the maintenance of the BBB 
[46, 47]. They also ensheath the synaptic cleft, and thus are 
now considered as the third part of the synapses [44, 48]. 
The end-feet of astrocytes participate in the control of synap-
tic neurotransmitters and ion concentrations, such as gluta-
mate and potassium, and therefore of the neurotransmission. 
Moreover, glial cells, particularly astrocytes, control the fate 
specification of adult neural stem cells. Indeed, astrocytes 
from hippocampus are capable of regulating neurogenesis by 
instructing the stem cells to adopt a neural fate [2]. Differen-
tiation of neuronal stem cells into astrocytes or neurons is 
highly relevant in maintaining brain function. The question 
of the issues of neuronal/glial cell identity, and neuronal-
glial interactions, in the context of adult neural stem cells 
biology, and their implication in neurogenesis during devel-
opment and adulthood, was recently reviewed [49-52]. 
Astrocytes are also involved in the control of synapto-
genesis [4, 6, 53-56]. In the mouse CNS this effect varies 
according to the brain regions and the type of neurons [57]. 
Astrocyte-derived cholesterol has been demonstrated to be 
responsible for an effect of astrocytes on synaptogenesis [3, 
58-60]. Astrocyte-derived estrogen increases synaptogenesis 
through the estrogen receptor-alpha in primary rat cortical 
neurons in culture [61]. Neurothrophins [62, 63], which are 
widely expressed in the developing and mature CNS and are 
well known for their role in promoting neuron survival and 
differentiation, and thrombospondins [64], which induce 
ultrastructurally normal synapses that are presynaptically 
active, are involved in the astrocyte-control of synaptogene-
sis. The astrocyte-control of synaptogenesis involving nu-
merous mechanisms therefore seems to be more complex 
than expected, more likely bilateral rather than unilateral. 
Astrocytes participate in neurotransmission by regulating 
concentrations of ions and neurotransmitters in the synaptic 
cleft, thereby controlling synaptic efficacy [5, 44, 65-67]. 
The synaptic concentration of neurotransmitters depends 
primarily upon presynaptic activity. However, the end-feet of 
astrocytes regulate this concentration, as was unambiguously 
demonstrated for glutamatergic and GABAergic synapses 
which are often involved in epilepsy [68, 69]. Astrocytes are 
responsible for the major part of glutamate uptake after its 
release from glutamatergic neurons [70]. The processes of 
astrocytes contain glutamate transporters (GLAST) that are 
more active than those of neural cells. Glutamate, after enter-
ing the astrocytes, is transformed into glutamine by glu-
tamine synthetase (GS), an enzyme that is essentially local-
ized to astrocytes and not to neurons [71]. Glutamine is 
therefore given to neurons in which it is metabolized either 
to glutamate or GABA (Fig. (1)). Moreover, the K
+ concen-
tration of the synaptic cleft is also regulated by the end-feet 
of astrocytes [72-75]. In addition, the active roles of extra-
synaptic neurotransmitter receptors and their relevance to 
neurovascular coupling, and of exocytosis of neurotransmit-
ters from astrocytes, have recently been reviewed [67, 76-
78], and the implication of these roles in epilepsy have been 
evoked [79-81]. Astrocytes contribute to the control of neu-
rotransmission using additional mechanisms: (i) they synthe-
size a glia-derived soluble acetylcholine-binding protein 
(AChBP), which is a naturally occurring analog of the 
ligand-binding domains of the nicotinic acetylcholine recep-
tors (nAChRs) [7]. This lure, or fake, receptor contributes to 
the regulation of acetylcholine content in the cholinergic 
synapses, by capturing acetylcholine. (ii) astrocytes produce 
a protein, the tumor necrosis factor alpha (TNF), which 
enhances synaptic efficacy by increasing surface expression 
of AMPA receptors [8]. All these events may influence neu-
ronal excitability and thus epileptogenesis. 
Glial cells, particularly astrocytes, should therefore be 
regarded as active partners of both the neuron and the syn-
apse in terms of regulators of their synthesis and efficacy. 
These cells participate in neurotransmission through their 
effects on neurons and synapses, and through their processes 
of information via the astrocyte network. The complexity of 
neural information and brain organization is reinforced by 
new considerations that we have to take into account for the 
most abundant cells in the CNS, namely glial cells. 
4.2. Astrocytes as Energy Providers to Neurons 
It is now thought that astrocytes also largely contribute to 
fuel neurons during pathological conditions, such as during 
periods of intense neural activity when energy demand ex-
ceeds the supply of glucose from the blood. This idea might 
also apply during normal conditions. Indeed, two possibili-
ties might exist to fuel neurons [82, 83]. Firstly, glucose 
enters astrocytes where it is metabolized down to lactate that 
is given to neurons to supply their energy demands. This is 
the astrocytes-neuron lactate shuttle hypothesis (ANLSH) 
[84-88]. Secondly, glucose enters neurons where it is utilized 
as the main source of energy. This is the conventional hy-
pothesis. 
4.2.1. Glucose Entering the Brain 
Glucose is the main source of brain energy. Blood glu-
cose has therefore first to cross the endothelial cell capillar-
ies whose tight junctions constitute the BBB, then the inter-
cellular area and the membranes of end-feet of astrocytes, 
and lastly the neuron membranes. GLUT proteins deliver 
glucose from the circulatory system to the brain. The mi-
crovascular endothelial cells and astrocytes contain GLUT1, 
while neurons contain both GLUT1 and GLUT3. Under 
normal conditions there is tightly limited in vivo expression 
of 45 kDa GLUT1 in neurons [89-92]. GLUT3 was cloned 
from a variety of mammalian brain cDNA libraries, and in 
the brain it has been localized almost exclusively to neurons 
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of the brain [97-101], it is quite possible that neurons are 
capable of taking it up and metabolizing it. Indeed, Simpson 
et al. [102] calculated that GLUT3 has both a higher affinity 
for glucose than GLUT1, and at least a fivefold greater 
transport capacity than GLUT1. They concluded that as there 
are approximately the same number of GLUT1 on glial and 
endothelial cells, the combination of lower Km and higher 
capacity enables the neurons preferential access to available 
glucose. In addition to this glucose uptake by neurons, it may 
be possible that astrocyte metabolism contributes to feeding 
neurons according to the ANLSH (Fig. (1)). Indeed, it seems 
likely that glucose enters astrocytes, in which it is metabo-
lized to lactate through the glycolysis pathway, and that 
astrocytes provide neurons with lactate as fuel [87, 103-113]. 
Neurons are therefore provided with a metabolite that can be 
rapidly used by the Krebs cycle (Fig. (1)). To fuel neurons, 
the ANLSH might be directly involved with glucose in paral-
lel with the conventional hypothesis. Indeed, it is highly 
conceivable that these two hypotheses are not mutually ex-
clusive to each other [114, 115], and the conventional hy-
pothesis would be the prevalent one in the normal state, 
while the ANLSH might be favored in pathological condi-
tions. Putatively, in pathologies such as epilepsy other forms 
of abnormal carbohydrate metabolism may also occur (see 
below). 
In addition to glucose transporters the glycolytic product 
of glucose metabolism, lactate, is transported in and out of 
neural cells by monocarboxylate transporters (MCT), MCT1 
in capillaries [116] and MCT2 in neurons [116-118]. The 
specific localization of these various transporters is in 
agreement with the ANLSH between astrocytes and neurons 
[87, 104-108, 111, 119] as summarized in Fig. (1). 
4.2.2. Glycogen Synthesis and Degradation 
The synthesis of glycogen inside the brain is essentially 
due to astrocytes [120] and microgliocytes and not to neu-
rons, as the latter do not contain glycogen synthase (GlyS) 
[103], while the two former cells have this enzyme. Never-
theless neurons, which are capable of gluconeogenesis [121-
123], are unable to accumulate glycogen [103, 124-126]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Schematic representation of the glucose-lactate shuttle between neurons and astrocytes (adapted from Pellerin [119], and Cloix 
[144]). Gln: glutamine, GlyS: glycogen synthase, GP: glycogen phosphorylase, GS: glutamine synthetase, GLAST, GLT-1: Na
+-glutamate 
co-transporter, Glu: glutamate, Lac: lactate, LDH5: Lactate dehydrogenase 5, MCT: monocarbohydrate transporter, NA: noradrenaline, Pyr: 
pyruvate, VIP: vasointestinal peptide. Epilepsy and Brain Glycogen Content  Current Medicinal Chemistry,  2009 Vol. 16, No. 7      845 
Inside astrocytes, glycogen synthesis might be performed 
using G-6-P coming either from glucose or from glu-
coneogenesis. Glycogen is therefore accumulated inside 
astrocytes [110, 111, 124, 127], and when energy is in high 
demand by neurons astrocytic glycogen might be metabo-
lized down to lactate [88, 109, 119, 128, 129]. Astrocytic 
glycogen could therefore be considered as an energy-store 
for neurons [130-133], in addition to lactate-derived from 
blood glucose through glycolysis (conventional hypothesis), 
this latter being possible both in neurons and astrocytes [106, 
124, 134-136], although during convulsions in which neu-
rons have a high-energy demand, obtaining glucose via the 
blood stream might not be sufficient. The astrocytic energy-
store might therefore be used through glycogen degradation 
that is performed by glycogen phosphorylase (GP), which is 
essentially expressed in astrocytes [106, 124]. Moreover, 
astrocytes contain receptors for glycogenolytic neurotrans-
mitters, such as noradrenaline [108, 137] or vasointestinal 
peptide [104, 138-140]. K
+ ions also have an acute glyco-
genolytic action on astrocytes [128, 141]. In fine, the preced-
ing neurotransmitter and ion effects, with their glyco-
genolytic potencies [105, 109-112, 142, 143], contribute to 
the production of lactate. Astrocytes therefore represent a 
source of energy to neurons [144], and they perform this role 
by various means, such as glycogenolysis and glycolysis. 
4.2.3. In Vivo Glycogen as Brain Function Marker 
Brain glycogen content is lower than that of liver and 
muscle. Nevertheless, the glycogen content of the CNS is 
nowadays also regarded as relevant in brain functions. Gly-
cogen synthesis and breakdown in the brain are beginning to 
be considered as relevant in normal brain functions, and in 
brain pathologies. Targeting research on brain glycogen 
pathways will be promising for both diagnosis and therapy. 
However, in terms of diagnosis, the in vivo measurement of 
brain glycogen content and synthesis is a challenge for the 
future, although the use of injection of [1-
13]C-glucose has 
made possible the non-invasive measurement of brain glyco-
gen content and turnover in both humans [145, 146] and rats 
[132, 133, 147-149]. These advances in the determination of 
brain glycogen will create a new understanding of its func-
tions, roles and metabolism in both normal and in pathologi-
cal conditions [110, 111, 130, 131, 150]. Once this difficult 
step has been overcome new tools will emerge to challenge 
brain glycogen in brain pathologies, and to target it as a 
treatment. 
5. MSO-INDUCED EPILEPSY 
Among the various epileptic or seizure-induced models, 
one of them is associated with both crisis and a specific 
increase in brain glycogen content [124, 125, 151-156]. This 
model corresponds to seizures induced by a derivative of 
methionine, namely methionine sulfoximine (MSO). 
5.1. Discovery of MSO 
MSO has been described as the chemical responsible for 
seizures induced in various animals after consumption of 
agenized flour, during the mid-1950s [157-159]; and it was 
therefore used to induce seizures in different animals, essen-
tially rats and mice with characterized EEG alterations be-
fore and during seizures [124, 154, 160, 161]. Moreover, 
some plants of the Cnestis genus, from Madagascar and 
Asia, were used to kill running dogs by causing severe con-
vulsions. The active compound in the seeds of Cnestis pal-
ada [162], and in the roots of Cnestis glabra and Cnestis 
polyphylla [163], was identified as MSO. 
5.2. MSO as an Epileptogenic Molecule 
Animals develop seizures after intraperitoneal admini-
stration of MSO, and such seizures mimic the human “grand 
mal”. They are characterized by disequilibrium, fits, running, 
myoclony and myotony, with EEG modifications. Animals 
developed epileptiform seizures 6-8 hours after MSO dosing 
(pre-convulsive period). The seizures were recurrent over 
24-48 hours (convulsive or ictal period), and the animals 
then recovered normal behavior (post-convulsive period) 
[124, 151, 164]. During this long pre-convulsive period, the 
animals present ataxia, akinesia, and equilibrium disorders. 
MSO strongly resembles glutamate, and it has been sug-
gested that it can induce seizures by mimicking the effect of 
this excitatory amino-acid [165, 166]. Indeed, if MSO can 
replace glutamate in the synaptic cleft, it could stimulate 
neurotransmission and therefore induce seizures, but this 
mechanism of action is still not clearly understood. In addi-
tion, MSO has also been described as an irreversible inhibi-
tor of GS [166]. Such an inhibition might therefore induce a 
putative increase of glutamate, which has been suggested as 
being responsible for the MSO-dependent convulsions [166]. 
Nonetheless, some reports [167-170] describe a decrease in 
brain glutamate content after the administration of a convul-
sive dose of MSO in rats, rather than the expected increase; 
but chronic inhibition of brain GS by MSO did not induce 
seizures in mice [171]. The involvement of GS inhibition by 
MSO in the MSO-dependent convulsions is therefore con-
troversial, and may not even be responsible for MSO-
dependent seizures. 
6. MSO AS A GLYCOGENIC MOLECULE 
Searches are based on clinical approaches, with the need 
to know where the epileptic foci are localized. Such localiza-
tion depends on both EEG and medical imageries. The latter 
are based on various mechanisms; the uptake of glucose 
analogs represents one of them [21-23]. This allowed the 
demonstration that epileptic foci are hypermetabolic during 
crisis [23], and hypometabolic during the interictal period 
[22]. Such a hypometabolism is a reflection of either an 
intrinsic decrease of cellular glucose uptake, or an intrinsic 
high level of capacity of brain production of energy, or both. 
The intrinsic increase in brain energy capacity may be due to 
various cell alterations, such as glycolysis, gluconeogenesis 
or glycogenesis; the latter resulting in accumulation of gly-
cogen. Such an increase in glycogen content is difficult to 
demonstrate in humans, although it has been shown that 
brain biopsies obtained from the hippocampus of epileptic 
patients contained high glycogen content in comparison with 
grey and white matter [172]. Such a high level of glycogen 
could contribute to high-energy demands by neurons during 
synchronization of their activities. Indeed, during seizures 
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their high activities, this energy might come from different 
sources: blood supply, neuron glycolysis and astrocyte 
source. When the first two sources are depleted the astrocyte 
glycogen might be mobilized, and astrocyte glycogenolysis 
could then generate lactate, which could be transferred to the 
neurons. 
In MSO-dependent seizures the accumulation of brain 
glycogen is observable during the pre-convulsive period 
before crisis, demonstrating that such an accumulation is not 
a consequence of seizures [124-126, 151, 164]. This high 
level of glycogen and its highest augmentation are specifi-
cally localized in the cortex and cerebellum, and more pre-
cisely in astrocytes (Fig. (2)) [124-126]. Moreover, the ac-
tion of MSO on alterations in metabolism is also demonstra-
ble in cultured rat and mouse astrocytes, again showing that 
such metabolic effects are not consequences of seizures [124, 
151, 155, 164]. Conversely, a decrease of glycogen content 
is also observed in other models of induced seizures, for 
example seizures induced by homocysteic acid [173, 174], 
indoklon/flurothyl [175], PTZ [176], hypoglycemia [177], 
bicuculine [178, 179], and maximal electroshock [177]. The 
accumulation of glycogen is essentially due to astrocyte 
metabolism, although in progressive myoclonus epilepsy 
inclusion Lafora bodies, resembling abnormal glycogen, 
accumulate in this disease [180]. In addition, and contrary to 
previous data, it has been recently reported that mouse neu-
rons have enzymatic machinery for synthesizing glycogen 
[181]. Nonetheless, the accumulation of glycogen in MSO-
dependent seizures is specific to astrocytes, and might be 
relevant in the onset of seizures and in the maintenance of 
crisis [151, 164]. 
7. MSO EPILEPTOGENESIS IN RELATION WITH 
NEUROTRANSMISSION  
As the excitability of neurons is largely monitored by 
neurotransmitters many investigations have been devoted to 
abnormalities in neurotransmission during epilepsy [182-
184]; yet despite a large number of experiments we still have 
no clear explanation on the involvement of neurotransmis-
sion in epilepsy. The general believe is that of a defect in the 
inhibitory neuronal circuits related to GABA, and/or an 
enhancement of excitatory circuits related to glutamate. The 
difficulty with this idea is that many epileptogenic situations 
do not involve defects in either GABA or in glutamate neu-
rotransmissions. One illustration is the model created by 
organophosphoric compounds such as soman [185-187]. It is 
well established that soman principally targets cholinergic 
neurotransmission, and generates typical epileptic seizures 
involving EEG and convulsions. Moreover, many other 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2): Electron micrographs of sections made in the parietal cerebral cortex of mice after the administration of methionine sulfoximine. 
Swiss mice were intraperitoneally injected with 100 mg/kg of methionine sulfoximine (B) or with saline as control (A). After intracardiac 
perfusion of glutaraldehyde, the brain tissue were taken off, washed in buffered sucrose, post-fixed in osmium tetroxide, dehydrated in 
graded alcohol and propylene oxide, and embedded in Effapoxy. The sections were made and stained with uranyl acetate and lead citrate and 
then, examined in an electron microscope. In control, beta glycogen particles are rare. After methionine sulfoximine administration, glycogen 
as alpha and beta particles considerably increases. Gly: glycogen; magnification A and B: x 15000. Epilepsy and Brain Glycogen Content  Current Medicinal Chemistry,  2009 Vol. 16, No. 7      847 
models clearly involve catecholamine and indoleamine neu-
rotransmissions [182-184]. The impairment of different 
neurotransmission systems is thus surely able to generate a 
variety of epileptic seizure models in animals, and probably 
different kinds of epilepsies in human as well. We looked for 
changes in the content of many neurotransmitters in the brain 
of rodents developing seizures after an intraperitoneal ad-
ministration of the drug MSO. The aim was to discover any 
possible relationship between the impairment in neurotrans-
mission and the impairment in the brain carbohydrate me-
tabolism, and MSO-dependent convulsions. Briefly, MSO 
induced a decrease in dopamine and serotonin levels and an 
increase in acetylcholine, while the noradrenaline level 
showed only a small change [188-191]. Using both agonists 
and antagonists of these neurotransmitters we were able to 
modulate the seizures, except in the case of acetylcholine. At 
the same time MSO induced a large increase in glycogen 
content in all areas of the brain, as previously described 
[124-126, 151, 154, 164, 178]. 
The question now arises as to what neurotransmission 
impairment has to do with glycogen content in epileptogeny? 
Experiments in vivo or in vitro [192, 193], and our unpub-
lished data, show that the glycogen content in the brain is 
insensitive to changes in acetylcholine. So the involvement 
of a cholinergic system in glycogen accumulation induced by 
MSO in the brain is improbable. GABA may not cause MSO 
epileptic-like activity in rodents, nor a glycogen level in-
crease, because the level of this neurotransmitter is insensi-
tive to the convulsant [188]. Biogenic amines, such as 
catecholamines, indolamines and histamine, have been re-
ported to elicit glycogenolysis in the brains of various spe-
cies, including mammals [194-197]. As glycogen accumula-
tion is restricted to astrocytes in the brain and neurotransmit-
ter release to neurons, it is obvious that interactions between 
neurons and astrocytes are responsible for changes in the 
metabolism of glycogen and of catecholamines and in-
doleamines. In the case of MSO, the observed decrease in 
dopamine and in serotonin levels is in a good agreement with 
the increase in glycogen content in the brain. Does the neuro-
transmitter decrease therefore trigger the glycogen accumu-
lation, or does glycogen accumulation induce changes in the 
preceding biogenic neurotransmission system? At present 
our experimental data does not allow us to clearly identify 
the primer of change. One can speculate that MSO decreases 
dopamine and serotonin levels, and thus causes an imbalance 
between GlyS and GP activities, and that this change results 
in the glycogen level increase. We have also speculated on 
the possible sequestration of glucose by astrocytes under the 
effect of MSO. Primarily, astrocytes may incorporate mole-
cules of glucose into glycogen. Moreover, over the same 
period of time, via an enhanced gluconeogenesis, lactate and 
pyruvate that astrocytes can normally send to neurons as fuel 
are converted to G-1-P through gluconeogenesis pathway, 
which is polymerized as glycogen. Gluconeogenesis and 
glycogen accumulation in astrocytes deprive neurons of 
energy, and this may alter neuronal function which then 
results in epileptic-like activity [125].. We now need to find 
a robust experimental design that will able us to discriminate 
an epileptogenesis event primarily triggered by changes in 
glycogen content, or by changes in neurotransmission under 
the effect of MSO. 
8. RELATIONSHIP BETWEEN MSO EFFECTS 
After MSO administration glycogen content remains high 
during the convulsive period, and up to the post-convulsive 
period. We have demonstrated that both seizure latency and 
glycogen accumulation are dependent on genotype in mice 
[151, 164]. Using various inbred strains of mice [151, 164], 
we observe that the latency to MSO-dependent seizures 
varies (Fig. (3)). The strain C57BL/6J presents the longest 
latency (13.03 ± 0.45 h, n=92), and the lowest susceptibility 
toward MSO (ED50=60 mg/kg), while CBA/J presents the 
fastest latency (5.95 ± 0.06 h, n=63) and the highest suscep-
tibility toward MSO (ED50=30 mg/kg). The CBA/J strain is 
also unable to accumulate glycogen inside the brain during 
the preconvulsive period, as opposed to C57BL/6J that does. 
This accumulation of brain glycogen is specifically localized 
to astrocytes, as previously described [124-126]. Indeed, 
MSO induces an activation of gluconeogenesis by a specific 
increase in activity of the last irreversible gluconeogenic 
enzyme, fructose-1,6-bisphosphatase (FBPase). Increases in 
both FBPase and glycogen deposits are specifically localized 
to astrocytes [124-126, 155, 191]. In addition, primary cul-
tures of astrocytes from these two strains demonstrate that 
MSO induces accumulation of glycogen only in cultured 
astrocytes from C57BL/6L, which is mediated by the spe-
cific activation of gluconeogenesis [151]. 
The question of a causal link between glycogen accumu-
lation and seizures remains open. We have demonstrated that 
at the onset of MSO-dependent seizures the glycogen that 
was accumulated in cortices before convulsions returns to 
the basal level (Fig. (3)). Such a normalization of glycogen 
content occurred only in C57BL/6J mice and not in CBA/J 
ones [151]. These data suggested (i) a mobilization of the 
high level of brain glycogen at the onset of seizures, which is 
observed in mice having a long latency to MSO-dependent 
convulsions, and (ii) that the accumulated glycogen in brain 
might be used as energy supply when neurons are in a con-
vulsive state. We therefore hypothesized that these two MSO 
effects, i.e. the elevation of glycogen and its mobilization 
during seizures, might constitute a way to postpone seizures 
[151, 164]. Bi-directional selection of MSO sensitive and 
MSO resistant mice is under investigation, in order to verify 
such a hypothesis. Preliminary results suggest that glycogen 
can accumulate after MSO dosing to a greater extent in cor-
tices of MSO resistant mice than in MSO sensitive ones 
(unpublished data), confirming our hypothesis that high 
levels of glycogen could delay MSO-induced seizures [151, 
164]. 
9. CONCLUSIONS: POTENTIAL OF MSO-DEPEN-
DENT SEIZURES MODEL 
The MSO-dependent seizures model presents some ad-
vantages compared with other chemically-induced seizures. 
Our two most important concerns are as follows. (i) The 
existence of a long preconvulsive period during which it is 
possible to easily observe changes before the onset of sei-
zures might not be a consequence of crisis. (ii) This model 
associates an accumulation of brain glycogen with induction 
of seizures, and therefore allows the analyses of the relation-
ship between seizures and brain glycogen content. This 
consideration is relevant, as high brain glycogen content has 848    Current Medicinal Chemistry,  2009 Vol. 16, No. 7  Cloix and Hévor 
sideration is relevant, as high brain glycogen content has 
been described in human epilepsy [172]. Moreover, in MSO 
dependent seizures glycogen accumulates in the brain before 
the onset of seizures, and remains high during the convulsive 
period. Nevertheless, such a high brain glycogen content is 
mobilized at the onset of seizures and returns to high level 
thereafter. We therefore propose, that such an elevation of 
brain glycogen could contribute to the postponement of sei-
zures [151, 164], by mechanisms such as astrocyte glycogen 
mobilization, which provides neuron with energy. In the very 
near future brain glycogen will be regarded as a diagnostic 
tool, as well as a therapeutic target [144]. Furthermore, in 
vivo MRI analyses have been performed in various animal 
models of epilepsy demonstrating that such a tool is valuable 
and informative, and might provide a clarification of the 
mechanisms involved in epilepsy [198, 199]. 
10. CONCLUDING REMARKS 
Knowing all the mechanisms and biological events re-
sponsible for the various forms of human epilepsies still has 
a long way to go. Nevertheless, the numerous researches 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Effect of various doses of MSO, both in vivo (A, C) and in vitro (B) using two different strains of mice, C57BL/6J and CBA/J. A: 
Induction of seizures expressed as the percentage of convulsing mice as a function of MSO doses. B: Variation of glycogen determined in 
cultured astrocytes as a function of MSO doses. C: Variation of glycogen content of mice cortices sacrificed at either predetermined time T4 
and T24) or at the onset of seizures (Seiz). Adapted from Bernard-Hélary et al. [151]. Epilepsy and Brain Glycogen Content  Current Medicinal Chemistry,  2009 Vol. 16, No. 7      849 
performed using human approaches present a doorway to the 
subject, which is now fully open due to the experimental 
models developed to study this neuropathology. Even if 
much is still unknown, new developments are on the way to 
giving us a deeper insight into the underlying mechanisms. 
For example, the use of transgenic mice could provide us 
with a useful tool for the genetic “dissection” of various 
aspects of the pathology, and may eventually lead to a “full” 
understanding of epilepsies. In any event such goals depend 
upon a better knowledge of brain physiology, which in itself 
needs the development of new approaches, technologies and 
ideas. Concerning this new knowledge, the brain glycogen 
content might be considered as highly relevant, and its in 
vivo measurement of content and variation in humans during 
normal and pathological conditions will be soon possible 
[145, 146]. Such a determination will be highly useful for 
analyzing the potency and relevance of brain glycogen con-
tent, and its mobilization in patients during pathological 
conditions. 
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ABBREVIATIONS 
AMPA =  -amino-3-hydroxy-5-méthyl-4 isoazole 
propionic acid 
ANLSH = Astrocytes-neuron  lactate  shuttle  hypothesis 
BBB =  Blood-brain  barrier 
CNS  =  Central Nervous System 
EEG =  Electroencephalography 
FBPase =  Fructose-1,6-bisphosphatase 
G-1-P =  Glucose-1-phosphate 
G-6-P =  Glucose-6-phosphate 
GABA =  -aminobutyric acid 
GLAST = Na
+-glutamate co-transporter 
Gln =  Glutamine 
Glu =  Glutamate 
GLUT  =  Glucose transporter, facilitative type 
GlycS =  Glycogen  synthase 
GP =  Glycogen  phosphorylase 
GS =  Glutamine  synthetase 
kDa =  kilo  Dalton 
Lac =  Lactate 
LDH5  =  Lactate dehydrogenase, type 5 
MCT =  Monocarboxylate  transporters 
MSO =  Methionine  sulfoximine 
NMDA =  N-methyl-D-aspartate 
Pyr =  Pyruvate 
VIP =  Vasointestinal  peptide 
WHO  =  World Health Organization 
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